Chiesi Farmaceutici S.p.A.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chiesi Farmaceutici S.p.A.
The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.
Chiesi-owned Amryt and Krystal Biotech have approved treatments for epidermolysis bullosa but they only treat one subtype - dystrophic - and a single wound. Paradigm CEO Robert Ryan tells Scrip that SD-101, a topical cream he helped develop over 20 years ago, has the potential to be offer a far more extensive and efficacious solution for many more sufferers.
Amryt’s Filsuvez Wins English Funding For Butterfly Skin Disease, Sanofi’s Dupixent Rejected In New Indication
Amryt/Chiesi’s birch bark extract gel, Filsuvez, is the first ever treatment for epidermolysis bullosa, a group of rare skin disorders, to be recommended by NICE for English reimbursement.
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Cornerstone Therapeutics (Cardiokine, Inc.
- Critical Therapeutics, Inc.
- EKR Therapeutics Inc.)
- Torrex Chiesi Pharma
- Zymenex Holding A/S
- Atopix Therapeutics Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.